8-K: Femasys Amends Warrants, Appoints New Director

Femasys Inc. announced amendments to its outstanding notes and warrants, issued new Series D-1 Warrants, and appointed Kenneth D. Eichenbaum, M.D., M.S.E. to its Board of Directors.

Summary

• Femasys Inc. entered into an Omnibus Amendment and Consent Agreement on March 19, 2026, with Consenting Holders to amend certain Senior Secured Convertible Notes and Warrants.
• The amendment, effective December 31, 2025, removes the "Share Combination Event Adjustment" from the Notes and Warrants.
• As consideration for these amendments, each Lender will receive a Series D-1 Warrant, granting the right to acquire a number of shares of common stock equal to the shares underlying their Series A-1 Warrant.
• A total of 16,378,563 Series D-1 Warrants are being issued by the Company, with an exercise price of $0.58 per share.
• These Series D-1 Warrants are issued in reliance upon the exemption from registration requirements of the Securities Act of 1933, as amended, afforded by Section 4(a)(2) thereof, to accredited investors.
• Joshua Silverman resigned as a director of the Company, effective March 17, 2026, stating his decision was not due to any dispute or disagreement with the Company.
• Kenneth D. Eichenbaum, M.D., M.S.E. was appointed as a Class II director to the Board, effective March 18, 2026, and will serve as a member of the Nominating and Corporate Governance Committee.
• Dr. Eichenbaum's appointment was made pursuant to a board nomination right granted to Pointillist Global Macro Series of Pointillist Partners LLC (the Lead Lender) under the Securities Purchase Agreement dated November 3, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as moderately negative due to the significant potential for shareholder dilution from the issuance of over 16 million new warrants at a low exercise price, despite the positive aspect of resolving prior agreement ambiguities and strengthening the board with a new, relevantly experienced director.

Positives

• Resolution of potential ambiguities or issues by removing the "Share Combination Event Adjustment" from the Notes and Warrants, which could streamline future corporate actions.
• Appointment of Kenneth D. Eichenbaum, M.D., M.S.E., a board-certified anesthesiologist with extensive clinical and healthcare technology experience, potentially strengthening the Board's expertise and independence.
• The company secured consent from the Requisite Holders for the amendments, indicating alignment with key lenders and facilitating corporate actions.

Negatives

• Issuance of 16,378,563 Series D-1 Warrants, which, upon exercise, will result in significant dilution for existing shareholders.
• The exercise price of $0.58 for the Series D-1 Warrants could be below the current market price, further exacerbating the dilutive effect on existing equity.

Risks

• Potential for significant dilution from the exercise of 16,378,563 Series D-1 Warrants.
• Limitations on the exercise of warrants if beneficial ownership exceeds 9.99% (Maximum Percentage) of outstanding common stock, or 19.99% without stockholder approval as per Nasdaq rules, which could affect liquidity for warrant holders.
• The company's failure to timely deliver securities upon warrant exercise could lead to "Buy-In" remedies for holders, including cash payments or additional shares, potentially increasing company costs.
• Disputes regarding the determination of the exercise price or the arithmetic calculation of the number of warrant shares could lead to resolution by an independent investment bank, incurring fees and potential delays.

Future Outlook

The company will continue to use commercially reasonable efforts to obtain stockholder approval for warrant exercises exceeding Nasdaq's 19.99% limitation if required. Dr. Eichenbaum will stand for election by the stockholders at the 2026 annual meeting.

Management Comments

• Joshua Silverman's decision to resign was not due to any dispute or disagreement with the Company, or on any matter relating to the Company's operations, policies or practices.

Industry Context

StockSavvy.ai notes that the amendment of existing debt and equity instruments, coupled with the issuance of new warrants, is a common mechanism for companies to restructure financial obligations and maintain lender relationships, particularly in sectors requiring ongoing capital. The appointment of a director with clinical and healthcare technology experience aligns with the specialized nature of the medical device or biotechnology industry, where Femasys likely operates, emphasizing the need for relevant expertise on the board.

Management Changes

Corporate Governance

Related Party Transactions

• Jorey Chernett, principal of Pointillist Global Macro Series of Pointillist Partners LLC (the Lead Lender), is also listed as a Consenting Holder and signed the Amendment Agreement in his individual capacity.
• The Lead Lender, Pointillist Global Macro Series of Pointillist Partners LLC, holds a board nomination right under the Securities Purchase Agreement, allowing them to recommend a director to the company's board.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of new Series D-1 Warrants, which could negatively impact per-share value.
• Lenders (Consenting Holders): Received additional Series D-1 Warrants as consideration for agreeing to amendments, potentially increasing their equity upside and maintaining influence through board nomination rights.
• Board of Directors: Strengthened by the addition of a director with relevant industry expertise, Kenneth D. Eichenbaum, M.D., M.S.E., potentially enhancing strategic decision-making and oversight.

Next Steps

• Dr. Eichenbaum will stand for election by the stockholders at the 2026 annual meeting.
• The company will use commercially reasonable efforts to obtain stockholder approval if warrant exercises exceed Nasdaq's 19.99% limitation.

Key Dates

Recommendation

The issuance of over 16 million new Series D-1 Warrants at an exercise price of $0.58, coupled with the potential for further dilution, presents a significant negative outlook for existing shareholders. While the resolution of prior agreement ambiguities and the addition of a qualified director are minor positives, the substantial dilutive effect outweighs these, suggesting a 'sell' recommendation for investors concerned about equity value erosion.

Keywords

Femasys Inc., FEMY, SEC Filing, 8-K, Warrants, Convertible Notes, Omnibus Amendment, Director Resignation, Director Appointment, Corporate Governance, Equity Dilution, Nasdaq Capital Market, Accredited Investor, Securities Purchase Agreement